ADAPTABLE Inclusion/Exclusion

Slides:



Advertisements
Similar presentations
1 CAMELOT: Study Design A Morbidity and Mortality Study Patients with documented CAD on standard-of-care therapies* (n=1997) Clinical events (morbidity.
Advertisements

Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
Primary Aim To compare outcomes of participants with symptoms of stable angina or angina equivalent evaluated with an anatomic imaging strategy using CCTA.
Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction Results of the Antithrombotics.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.
The 2015 PCORI Annual Meeting: Progress in Building a Patient-Centered Comparative Clinical Effectiveness Research Community Innovative Features of the.
AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic Updates (CMS164) Change Review Process Meeting November 19, 2015 Jenna Williams-Bader.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.
Samuel Thomas Rayburn, III MD Cardiovascular Surgeon Jack Stephens Heart Institute April 25, 2015.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship Between Operator Volume and Adverse.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Procedural Outcomes of Chronic Total Occlusion Percutaneous.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Characteristics and Long-Term Outcomes of Percutaneous.
Glycated hemoglobin and long-term prognosis in patients with suspected stable angina pectoris without diabetes mellitus: A prospective cohort study  Eirik.
Total Occlusion Study of Canada (TOSCA-2) Trial
Douglas S. Bell, MD, PhD Leader, UCLA CTSI Informatics Program
Copyright © 2013 American Medical Association. All rights reserved.
Patient populations by study group figure 10
Successful CTO PCI Associated with Lower Mortality Risk
Volume 1: Chronic Kidney Disease
First time a CETP inhibitor shows reduction of serious CV events
Six-month–adjusted survival after aortic valve replacement (AVR) for severe aortic stenosis (AS) stratified by procedure and preoperative ejection fraction.
Chapter 4: Cardiovascular Disease in Patients with CKD
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
European Society of Cardiology 2003
Nat. Rev. Cardiol. doi: /nrcardio
Giuseppe Biondi Zoccai, MD
MACE rate among CAD severity groups (total 0
The American College of Cardiology Presented by Dr. Raimund Erbel
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Myocardial Revascularization for Patients With Diabetes: Coronary Artery Bypass Grafting or Percutaneous Coronary Intervention?  Serenella Castelvecchio,
New-Onset Postoperative Atrial Fibrillation and Long-Term Survival After Aortic Valve Replacement Surgery  Giovanni Filardo, PhD, MPH, Cody Hamilton,
Coronary revascularisation rate (total 5
Figure 4 Observational studies on multiple treatment strategies
Coronary artery bypass in patients with type 2 diabetes: Experience from the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial  Edward.
Donald S. Likosky, PhD, Stephen D. Surgenor, MD, Robert S
Association of neutrophils and future cardiovascular events in patients with peripheral artery disease  Markus Haumer, MD, Jasmin Amighi, MD, Markus Exner,
Off-pump versus on-pump coronary artery bypass grafting: Insights from the Arterial Revascularization Trial  Umberto Benedetto, MD, PhD, Douglas G. Altman,
Nat. Rev. Cardiol. doi: /nrcardio
Recent Temporal Changes in Atherosclerotic Cardiovascular Diseases in Ontario: Clinical and Health Systems Impact  Jack V. Tu, MD, PhD, Anam M. Khan,
Do the EXCEL and NOBLE Trial Results Change Meta-Analysis Findings?
Nat. Rev. Cardiol. doi: /nrcardio
Presented at TCT 2006.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Drug-eluting stents versus coronary artery bypass grafting for the treatment of coronary artery disease: A meta-analysis of randomized and nonrandomized.
One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: A.
Atlantic Cardiovascular Patient Outcomes Research Team
Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.
Glenn N. Levine et al. JACC 2011;58:e44-e122
Long-term outcome of dialysis patients in the United States with coronary revascularization procedures  Charles A. Herzog, M.D., Jennie Z. Ma, Allan J.
Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;
Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.
Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.
Transatlantic editorial: A comparison between European and North American guidelines on myocardial revascularization  Philippe Kolh, MD, PhD, Paul Kurlansky,
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.
Figure 9.1.a Causes of death in ESRD patients,
Adjusted. ORs for outcomes by maintenance P2Y12 treatment
Presentation transcript:

ADAPTABLE Inclusion/Exclusion Known atherosclerotic cardiovascular disease (ASCVD), defined by a history of myocardial infarction, coronary angiography showing ≥75% stenosis of at least one epicardial coronary vessel, or coronary revascularization procedure (coronary artery bypass surgery or percutaneous coronary intervention) Age ≥ 18 years No known intolerance to an aspirin dose of ≤ 325 mg/day (intolerance includes a true allergic reaction or a side effect, including gastrointestinal issues, that preclude using aspirin 325 mg/day) Access to the Internet or agreement to collect follow-up information by the Call Center from patients without Internet access Not currently using warfarin or novel anticoagulant (dabigatran, rivaroxaban, apixaban, edoxaban) Not pregnant or nursing an infant Estimated risk of a major cardiovascular event (MACE) >8% over next 3 years as evidenced by one or more of the following risk factors: age > 65 years, creatinine > 1.5, diabetes, known 3 vessel coronary artery disease, current cerebrovascular disease and/or peripheral artery disease, known ejection fraction <50%, current smoker. Able and willing to provide informed consent and agreeing to be followed through the Internet and/or through calls by the Call Center for the duration of the trial (maximum expected follow-up of 30 months) There will be no exclusion for any upper age limit or comorbid conditions.